Key result
Oral tetrahydrobiopterin inhibits atherogenesis and improves endothelial dysfunction in ApoE-knockout mice.
Why the study?
Although oral tetrahydrobiopterin (BH4) prevents endothelial dysfunction and vascular oxidative stress in rat models, its effect on atherogenesis remained unclear.
Does oral administration of tetrahydrobiopterin slow the progression of atherosclerosis in hypercholesterolemic apolipoprotein E-knockout mice?
Does oral administration of tetrahydrobiopterin slow the progression of atherosclerosis in hypercholesterolemic apolipoprotein E-knockout mice?
Oral tetrahydrobiopterin supplementation slows atherosclerosis progression and improves nitric oxide-mediated endothelial function by reducing vascular oxidative stress and inflammation in a murine model of hypercholesterolemia.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for oral tetrahydrobiopterin in atherosclerosis; human trials needed before clinical consideration.
OBJECTIVE: Although it has been reported that oral administration of tetrahydrobiopterin (BH4) prevents endothelial dysfunction and vascular oxidative stress in various rat models, the effect of treatment with BH4 on atherogenesis remains unclear. METHODS AND RESULTS: In this study, we investigated whether oral BH4 treatment might slow the progression of atherosclerosis using hypercholesterolemic apolipoprotein E-knockout mice. We report that ingesting BH4 in drinking water is sufficient to inhibit atherogenesis in mice. Furthermore, we report that BH4 treatment improves endothelial dysfunction and attenuates increased mRNA expression of NADPH oxidase components, as well as a number of inflammatory factors, such as LOX-1 and MCP-1, in the aortas of apolipoprotein E- knockout mice. CONCLUSION: Strategies such as oral administration of BH4 to ensure continuous BH4 availability may be effective in restoring nitric oxide-mediated endothelial function and limiting vascular disease and the progression of atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Hattori et al. (2007) studied Atherosclerosis and hypercholesterolemia. Tetrahydrobiopterin (BH4) was evaluated on Progression of atherosclerosis (atherogenesis). Oral tetrahydrobiopterin in drinking water inhibited atherogenesis, improved endothelial dysfunction, and attenuated aortic NADPH oxidase and inflammatory mRNA expression in ApoE-knockout mice.
Synapse has enriched 10 related papers. Consider them for comparative context: